BLUEFIN

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 04 Jun 2025 filing date already counts against anyone who files later.

Record

Serial number

99218525

Mark type

Stylized text

Filed

04 Jun 2025

Published for opposition

25 Nov 2025

Attorney of record

Keith Toms, Esq.

Goods and services

• Class 005 — Pharmaceuticals: Antibodies for medical purposes; Diagnostic biomarker reagents for medical purposes; Protein arrays for medical diagnosis purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes; Pharmaceutical preparations for the treatment of cancer, oncologic diseases and disorders, inflammation and immunity diseases and disorders, immunodeficiency diseases and disorders, genetic diseases and disorders, metabolic diseases and disorders, neurodegenerative diseases and disorders, kidney diseases and disorders, eye diseases and disorders, uveitis, glomerulosclerosis, glomerulonephritis, cardiovascular diseases and disorders
• Class 042 — Scientific and technological services: Pharmaceutical research and development; Research and development services in the field of antibodies; Providing medical and scientific research information; Consulting services in the field of pharmaceutical research and development; Consulting services in the field of biotechnology; Consulting services in the field of pharmacogenetics; Research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; Research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; Research and development in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; Research and development in the field of proteomics, transcriptomics, and bioinformatics

Owner

• Bluefin Biomedicine, Inc., Beverly, MA, US
• Bluefin Biomedicine, Inc., Beverly, MA, US

Prosecution history

• 20 Jan 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 25 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 25 Nov 2025 — PUBLISHED FOR OPPOSITION
• 19 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 27 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 24 Oct 2025 — ASSIGNED TO EXAMINER
• 10 Oct 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 04 Jun 2025 — APPLICATION FILING RECEIPT MAILED
• 04 Jun 2025 — NEW APPLICATION ENTERED